Calcitriol capsules 0.25 mcg for osteoporosis, chronic renal failure, hypoparathyroidism and osteomalacia

General information on Japanese Calcitriol capsules 0.25 mcg for osteoporosis, chronic renal failure, hypoparathyroidism and osteomalacia

Package details: 100 capsules

Manufacturer: Sawai Pharmaceutical Co., Ltd., Japan

Active ingredients: calcitriol (chemical formula C27H44O3)

Medical effect: Calcitriol capsules are effective for the treatment of osteoporosis, chronic renal failure, hypoparathyroidism and osteomalacia

Contraindications and precautions: Do not use for pregnant or breastfeeding women. Do not use for patients with hypercalcaemia or vitamin D intoxication.

If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.

Dosage and administration

1. For osteoporosis: for adults, take 1 capsule at a time, 2 times a day.
2. For chronic renal failure: for adults, take 1-3 capsules at a time, once a day.
3. For hypoparathyroidism and other diseases associated with abnormal vitamin D metabolism: for adults, take 2-8 capsules at a time, once a day.

The doctor in charge may adjust the dosage according to age and symptoms.

How effective are Calcitriol capsules 0.25 mcg from Japan for osteoporosis, chronic renal failure, hypoparathyroidism and osteomalacia?

Calcitriol is an active form of vitamin D3, naturally produced in the kidneys. As it is involved in the calcium absorption in the stomach, the lack of calcitriol leads to weakening of bones and various bone diseases. Calcitriol capsules increase calcium absorption in the small intestine and kidney, promote bone formation through direct effects on bone cells and suppress the secretion of parathyroid hormone in the blood.

Who should use Calcitriol capsules 0.25 mcg from Japan?

Calcitriol capsules are effective for the treatment of osteoporosis and to improve various symptoms in patients with chronic renal failure, hypoparathyroidism and rickets/osteomalacia, such as:

• hypocalcemia,
• numbness,
• tetany,
• abnormal perception,
• muscle weakness,
• bone pain,
• bone lesion.

Studies showed that calcitriol slows down bone less in a variety of populations, and can be used together with other bone-preserving agents as well (L. J. Peppone, S. Hebl et al. “The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review” // Osteoporosis International, 2010, 21(7): 1133–1149).